8-Bromo-7-(2-chlorobenzyl)-3-methyl-1-phenethyl-3,7-dihydropurine-2,6-dione | 303973-63-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 8-Bromo-7-(2-chlorobenzyl)-3-methyl-1-phenethyl-3,7-dihydropurine-2,6-dione
• 英文别名: 8-bromo-7-[(2-chlorophenyl)methyl]-3-methyl-1-(2-phenylethyl)purine-2,6-dione
• CAS: 303973-63-9
• 化学式: C₂₁H₁₈BrClN₄O₂
• 分子量: 473.757
• InChiKey: IVZDCXJVISUTFU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  58.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  8-bromo-7-(2-chlorobenzyl)-3-methyl-3,7-dihydropurine-2,6-dione 、 N,N-二甲基甲酰胺 、 乙基溴苯 、 potassium carbonate 以 乙酸乙酯 、 水 为溶剂， 反应 20.0h， 以to afford compound 53B as white crystals的产率得到8-Bromo-7-(2-chlorobenzyl)-3-methyl-1-phenethyl-3,7-dihydropurine-2,6-dione
  参考文献：
  名称：

  Hetrocyclic compounds that are inhibitors of the enzyme DPP-IV

  摘要：

  本发明涉及治疗活性和选择性的DPP-IV酶抑制剂，包括该化合物的药物组合物和使用这些化合物制造药物来治疗与DPP-IV酶失活相关的蛋白质相关疾病，例如2型糖尿病和肥胖症。本发明的抑制剂是新型嘌呤衍生物，在嘌呤骨架的8位连接了一种二胺。

  公开号：

  US20030199528A1

文献信息

• HETEROCYCLIC COMPOUNDS THAT ARE INHIBITORS OF THE ENZYME DPP-IV
  申请人：NOVO NORDISK A/S

  公开号：EP1463727A2

  公开（公告）日：2004-10-06
• [EN] HETEROCYCLIC COMPOUNDS THAT ARE INHIBITORS OF THE ENZYME DPP-IV<br/>[FR] COMPOSES HETEROCYCLIQUES CONSTITUANT DES INHIBITEURS DE L'ENZYME DPP-IV
  申请人：NOVO NORDISK AS

  公开号：WO2003024965A2

  公开（公告）日：2003-03-27

  The present invention relates to therapeutically active and selective inhibitors (Formula II)of the enzyme DPP-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated with proteins that are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity. The present inhibitors are novel purine derivatives, attached at position 8 of the purine skeleton to a diamine.
• Hetrocyclic compounds that are inhibitors of the enzyme DPP-IV
  申请人：——

  公开号：US20030199528A1

  公开（公告）日：2003-10-23

  The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated with proteins that are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity. The present inhibitors are novel purine derivatives, attached at position 8 of the purine skeleton to a diamine.

  本发明涉及治疗活性和选择性抑制酶DPP-IV的化合物，包括药物组合物和利用这些化合物制造用于治疗与受DPP-IV失活的蛋白质相关的疾病的药物，如2型糖尿病和肥胖症。本发明的抑制剂是新颖的嘌呤衍生物，在嘌呤骨架的位置8处连接到二胺。